Lupin launches testosterone gel, third launch in April

Pharma major Lupin Limited, in a press release announced that it launched Testosterone Gel, on Friday. The company received USFDA approval for the same on Thursday.

The company announced that the Testosterone Gel, 1.62 per cent is launched. The medicine will be made available in 20.25 mg and 1.25 g pump actuation. Lupin had received US Food and Drug Administrations approval for this earlier. Lupin's Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62 per cent. The requirement of the above medicine is indicated in replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone. The specific conditions mentioned are such as Primary hypogonadism and hypogonadotropic hypogonadism.

Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had an annual sales of approximately USD 893 million in the US (IQVIA MAT December 2018).

Lupin is engaged in developing and delivering branded and generic formulations. It also further produces biotechnology products and APIs globally. It is also a major player in Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAID space.

At 14:45 hours, the stock of Lupin was trading at Rs. 827.85 per share, higher by 2.35 per cent on BSE.